Common Electrophysiology Biomarkers Collected at Home Robustly Track Depression Recovery With Deep Brain Stimulation

Subcallosal cingulate cortex (SCC) deep brain stimulation (DBS) can provide relief for individuals with Treatment Resistant Depression (TRD), but ongoing clinical management remains challenging due to nonspecific symptom fluctuations that can obscure core depression recovery on standard rating scales. Objective, stable biomarkers that selectively track the therapeutic effects of SCC DBS are therefore essential for developing principled decision support systems to guide stimulation adjustments. Recent bidirectional DBS systems enable chronic recording of local field potentials (LFPs) and prior work using the Activa PC+S device identified an electrophysiological signature of stable clinical recovery. However, translation to practical clinical deployment requires demonstrating that this biomarker is robustly generalizable, specific to the impact of the DBS therapy, and deployable in real-world recording contexts. To address this need, we developed an at-home SCC LFP data collection platform (built on the Medtronic Summit RC+S system) enabling at home data collection for a new cohort of ten SCC DBS participants with TRD (ClinicalTrials.gov identifier NCT04106466 ). Using longitudinal LFP recordings collected from this system, we report findings demonstrating that the previously reported biomarker of stable recovery generalizes across subject cohorts and devices, is robust to common potential confounds (including time of day and stimulation status), and shows symptom specificity, sensitivity and stability necessary to support clinical decision making. Across both cohorts, biomarker changes show relationships to pre-DBS white matter structure and network function measured using diffusion MRI and resting-state functional MRI (rsFMRI). These findings replicating and extending previous findings support the biomarker's utility as a foundation for scalable, electrophysiology-informed decision support in SCC DBS.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-04-20
DOI
https://doi.org/10.64898/2026.04.13.26350107
Primary Topic
Neurological disorders and treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Common Electrophysiology Biomarkers Collected at Home Robustly Track Depression Recovery With Deep Brain Stimulation

Christopher J. Rozell, Tanya Nauvel, Helen S. Mayberg, Mosadoluwa Obatusin et al.
medRxiv
Neurological disorders and treatments
article

Common Electrophysiology Biomarkers Collected at Home Robustly Track Depression Recovery With Deep Brain Stimulation

Christopher J. Rozell, Tanya Nauvel, Helen S. Mayberg, Mosadoluwa Obatusin, Sankaraleengam Alagapan, Aida Razavilar, Ha Neul Song, Stephen Heisig, Ki Sueng Choi, Jungho Cha, Patricio Riva‐Posse, Allison C. Waters, Tim Dennison, Elif Ceren Fitoz, Shreesh Karjagi, Maryam Khalid, Parisa Sarikhani, Isha Trivedi, Romain Guignon, Jessa Alexander, Shannon O'Neill, Martijn Figee, Jamie Gowatsky, Brian Kopell, Gutemberg Bobby Forestal
article en

Abstract

Subcallosal cingulate cortex (SCC) deep brain stimulation (DBS) can provide relief for individuals with Treatment Resistant Depression (TRD), but ongoing clinical management remains challenging due to nonspecific symptom fluctuations that can obscure core depression recovery on standard rating scales. Objective, stable biomarkers that selectively track the therapeutic effects of SCC DBS are therefore essential for developing principled decision support systems to guide stimulation adjustments. Recent bidirectional DBS systems enable chronic recording of local field potentials (LFPs) and prior work using the Activa PC+S device identified an electrophysiological signature of stable clinical recovery. However, translation to practical clinical deployment requires demonstrating that this biomarker is robustly generalizable, specific to the impact of the DBS therapy, and deployable in real-world recording contexts. To address this need, we developed an at-home SCC LFP data collection platform (built on the Medtronic Summit RC+S system) enabling at home data collection for a new cohort of ten SCC DBS participants with TRD (ClinicalTrials.gov identifier NCT04106466 ). Using longitudinal LFP recordings collected from this system, we report findings demonstrating that the previously reported biomarker of stable recovery generalizes across subject cohorts and devices, is robust to common potential confounds (including time of day and stimulation status), and shows symptom specificity, sensitivity and stability necessary to support clinical decision making. Across both cohorts, biomarker changes show relationships to pre-DBS white matter structure and network function measured using diffusion MRI and resting-state functional MRI (rsFMRI). These findings replicating and extending previous findings support the biomarker's utility as a foundation for scalable, electrophysiology-informed decision support in SCC DBS.

medRxiv
Georgia Institute of Technology (US), Emory University (US), University of Oxford (GB), Icahn School of Medicine at Mount Sinai (US)
Openalex Percentile: Top 14%
Neurological disorders and treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.